Company intelligence / Profile preview

BioRestorative Therapies

Melville, New York, United Statesbiorestorative.com ↗

Ownership: Public · BRTX
Development stage: Phase 2

Overview

BRTX-100 has received FDA Fast Track designation for chronic lumbar disc disease. Phase 2 clinical trial is ongoing with positive safety data reported. No serious adverse events have occurred in the trial. The FDA has also cleared an IND for a Phase 2 trial of BRTX-100 for chronic cervical discogenic pain.

Therapeutic areas: EndocrinologyNeurology
Modalities: Stem cell therapiesCell-based therapeuticsTissue protocols
Industry: Biotech

Drug pipeline

3 assets

BRTX-100

2 more assets in the full pipeline.

Request access →

Financials

Market cap: $3.8M
Total revenue: $23.2K
Enterprise value: $254.4K

Beyond the preview

Go deeper on BioRestorative Therapies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioRestorative Therapies.

Explore the full profile